OTCMKTS:PXXLF - Poxel Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.00
  • Forecasted Upside: 213.43 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$6.70
+0.30 (1.20%)

This chart shows the closing price for PXXLF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Poxel Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PXXLF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PXXLF

Analyst Price Target is $21.00
▲ +213.43% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Poxel in the last 3 months. The average price target is $21.00, with a high forecast of $21.00 and a low forecast of $21.00. The average price target represents a 213.43% upside from the last price of $6.70.

This chart shows the closing price for PXXLF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Poxel.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/24/2021JMP SecuritiesReiterated RatingBuy$21.00
6/23/2020JMP SecuritiesInitiated CoverageOutperform
(Data available from 9/28/2016 forward)

News Sentiment Rating

0.97 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/2/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Poxel logo
Poxel S.A., a biopharmaceutical company, develops drugs for metabolic diseases with primary focus on type II diabetes. Its lead product is Imeglimin, an oral anti-diabetic candidate, which is in Phase III clinical development stage that targets the organs of diabetes, such as pancreas, liver, and muscles. The company is also developing PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in Phase IIa clinical trial that controls body energy metabolism and treats chronic metabolic diseases, such as non-alcoholic steatohepatitis (NASH). It has a licensing agreement with Enyo Pharma for the development of PXL007 (EYP001), an FXR agonist that is in Phase I study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in phase I clinical trials for the treatment of NASH. The company was founded in 2009 and is headquartered in Lyon, France.
Read More

Today's Range

Now: $6.70
Low: $6.70
High: $6.70

50 Day Range

MA: $6.84
Low: $6.47
High: $8.19

52 Week Range

Now: $6.70
Low: $6.47
High: $8.19

Volume

N/A

Average Volume

2,533 shs

Market Capitalization

$161.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Poxel?

The following Wall Street sell-side analysts have issued research reports on Poxel in the last year: JMP Securities, and Zacks Investment Research.
View the latest analyst ratings for PXXLF.

What is the current price target for Poxel?

1 Wall Street analysts have set twelve-month price targets for Poxel in the last year. Their average twelve-month price target is $21.00, suggesting a possible upside of 213.4%. JMP Securities has the highest price target set, predicting PXXLF will reach $21.00 in the next twelve months. JMP Securities has the lowest price target set, forecasting a price of $21.00 for Poxel in the next year.
View the latest price targets for PXXLF.

What is the current consensus analyst rating for Poxel?

Poxel currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PXXLF will outperform the market and that investors should add to their positions of Poxel.
View the latest ratings for PXXLF.

How do I contact Poxel's investor relations team?

Poxel's physical mailing address is 259-261 Avenue Jean Jaures, Lyon I0, 69007. The company's listed phone number is 33-4-37-37-20-10 and its investor relations email address is [email protected] The official website for Poxel is www.poxel.com.